CRISPR and gene‑editing took center stage as leaders framed 2025 as a landmark year of in vivo and personalized editing advances. In a wide‑ranging interview, Jennifer Doudna reflected on recent clinical milestones — including in‑patient CRISPR interventions and the FDA approvals of CRISPR‑based therapies — and on the field’s pathway toward broader clinical access. Editorial roundups and industry retrospectives cataloged multiple 'firsts' across gene therapy, base editing and personalized mRNA approaches, while also underscoring regulatory, manufacturing and ethical hurdles that remain. Those pieces emphasized translation from n‑of‑1 successes toward scalable, reproducible therapies. The discourse signals two parallel pressures for gene‑editing firms: accelerate clinical translation where data exist and simultaneously build manufacturing, regulatory and access strategies to make treatments reproducible and affordable.